Cargando…

Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers

Obesity is a multifactorial disease and is associated with an increased risk of developing metabolic syndrome and co-morbidities. Dysregulated expansion of the adipose tissue during obesity induces local tissue hypoxia, altered secretory profile of adipokines, cytokines and chemokines, altered profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sajid, Sehar, Zariwala, Mohammed Gulrez, Mackenzie, Richard, Turner, Mark, Nell, Theo, Bellary, Srikanth, Renshaw, Derek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182642/
https://www.ncbi.nlm.nih.gov/pubmed/35684160
http://dx.doi.org/10.3390/nu14112360
_version_ 1784724085483241472
author Sajid, Sehar
Zariwala, Mohammed Gulrez
Mackenzie, Richard
Turner, Mark
Nell, Theo
Bellary, Srikanth
Renshaw, Derek
author_facet Sajid, Sehar
Zariwala, Mohammed Gulrez
Mackenzie, Richard
Turner, Mark
Nell, Theo
Bellary, Srikanth
Renshaw, Derek
author_sort Sajid, Sehar
collection PubMed
description Obesity is a multifactorial disease and is associated with an increased risk of developing metabolic syndrome and co-morbidities. Dysregulated expansion of the adipose tissue during obesity induces local tissue hypoxia, altered secretory profile of adipokines, cytokines and chemokines, altered profile of local tissue inflammatory cells leading to the development of low-grade chronic inflammation. Low grade chronic inflammation is considered to be the underlying mechanism that increases the risk of developing obesity associated comorbidities. The glucocorticoid induced protein annexin A1 and its N-terminal peptides are anti-inflammatory mediators involved in resolving inflammation. The aim of the current study was to investigate the role of annexin A1 in obesity and associated inflammation. To achieve this aim, the current study analysed data from two feasibility studies in clinical populations: (1) bariatric surgery patients (Pre- and 3 months post-surgery) and (2) Lipodystrophy patients. Plasma annexin A1 levels were increased at 3-months post-surgery compared to pre-surgery (1.2 ± 0.1 ng/mL, n = 19 vs. 1.6 ± 0.1 ng/mL, n = 9, p = 0.009) and positively correlated with adiponectin (p = 0.009, r = 0.468, n = 25). Plasma annexin A1 levels were decreased in patients with lipodystrophy compared to BMI matched controls (0.2 ± 0.1 ng/mL, n = 9 vs. 0.97 ± 0.1 ng/mL, n = 30, p = 0.008), whereas CRP levels were significantly elevated (3.3 ± 1.0 µg/mL, n = 9 vs. 1.4 ± 0.3 µg/mL, n = 31, p = 0.0074). The roles of annexin A1 were explored using an in vitro cell based model (SGBS cells) mimicking the inflammatory status that is observed in obesity. Acute treatment with the annexin A1 N-terminal peptide, AC2-26 differentially regulated gene expression (including PPARA (2.8 ± 0.7-fold, p = 0.0303, n = 3), ADIPOQ (2.0 ± 0.3-fold, p = 0.0073, n = 3), LEP (0.6 ± 0.2-fold, p = 0.0400, n = 3), NAMPT (0.4 ± 0.1-fold, p = 0.0039, n = 3) and RETN (0.1 ± 0.03-fold, p < 0.0001, n = 3) in mature obesogenic adipocytes indicating that annexin A1 may play a protective role in obesity and inflammation. However, this effect may be overshadowed by the continued increase in systemic inflammation associated with rapid tissue expansion in obesity.
format Online
Article
Text
id pubmed-9182642
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91826422022-06-10 Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers Sajid, Sehar Zariwala, Mohammed Gulrez Mackenzie, Richard Turner, Mark Nell, Theo Bellary, Srikanth Renshaw, Derek Nutrients Article Obesity is a multifactorial disease and is associated with an increased risk of developing metabolic syndrome and co-morbidities. Dysregulated expansion of the adipose tissue during obesity induces local tissue hypoxia, altered secretory profile of adipokines, cytokines and chemokines, altered profile of local tissue inflammatory cells leading to the development of low-grade chronic inflammation. Low grade chronic inflammation is considered to be the underlying mechanism that increases the risk of developing obesity associated comorbidities. The glucocorticoid induced protein annexin A1 and its N-terminal peptides are anti-inflammatory mediators involved in resolving inflammation. The aim of the current study was to investigate the role of annexin A1 in obesity and associated inflammation. To achieve this aim, the current study analysed data from two feasibility studies in clinical populations: (1) bariatric surgery patients (Pre- and 3 months post-surgery) and (2) Lipodystrophy patients. Plasma annexin A1 levels were increased at 3-months post-surgery compared to pre-surgery (1.2 ± 0.1 ng/mL, n = 19 vs. 1.6 ± 0.1 ng/mL, n = 9, p = 0.009) and positively correlated with adiponectin (p = 0.009, r = 0.468, n = 25). Plasma annexin A1 levels were decreased in patients with lipodystrophy compared to BMI matched controls (0.2 ± 0.1 ng/mL, n = 9 vs. 0.97 ± 0.1 ng/mL, n = 30, p = 0.008), whereas CRP levels were significantly elevated (3.3 ± 1.0 µg/mL, n = 9 vs. 1.4 ± 0.3 µg/mL, n = 31, p = 0.0074). The roles of annexin A1 were explored using an in vitro cell based model (SGBS cells) mimicking the inflammatory status that is observed in obesity. Acute treatment with the annexin A1 N-terminal peptide, AC2-26 differentially regulated gene expression (including PPARA (2.8 ± 0.7-fold, p = 0.0303, n = 3), ADIPOQ (2.0 ± 0.3-fold, p = 0.0073, n = 3), LEP (0.6 ± 0.2-fold, p = 0.0400, n = 3), NAMPT (0.4 ± 0.1-fold, p = 0.0039, n = 3) and RETN (0.1 ± 0.03-fold, p < 0.0001, n = 3) in mature obesogenic adipocytes indicating that annexin A1 may play a protective role in obesity and inflammation. However, this effect may be overshadowed by the continued increase in systemic inflammation associated with rapid tissue expansion in obesity. MDPI 2022-06-06 /pmc/articles/PMC9182642/ /pubmed/35684160 http://dx.doi.org/10.3390/nu14112360 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sajid, Sehar
Zariwala, Mohammed Gulrez
Mackenzie, Richard
Turner, Mark
Nell, Theo
Bellary, Srikanth
Renshaw, Derek
Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers
title Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers
title_full Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers
title_fullStr Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers
title_full_unstemmed Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers
title_short Suppression of Anti-Inflammatory Mediators in Metabolic Disease May Be Driven by Overwhelming Pro-Inflammatory Drivers
title_sort suppression of anti-inflammatory mediators in metabolic disease may be driven by overwhelming pro-inflammatory drivers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182642/
https://www.ncbi.nlm.nih.gov/pubmed/35684160
http://dx.doi.org/10.3390/nu14112360
work_keys_str_mv AT sajidsehar suppressionofantiinflammatorymediatorsinmetabolicdiseasemaybedrivenbyoverwhelmingproinflammatorydrivers
AT zariwalamohammedgulrez suppressionofantiinflammatorymediatorsinmetabolicdiseasemaybedrivenbyoverwhelmingproinflammatorydrivers
AT mackenzierichard suppressionofantiinflammatorymediatorsinmetabolicdiseasemaybedrivenbyoverwhelmingproinflammatorydrivers
AT turnermark suppressionofantiinflammatorymediatorsinmetabolicdiseasemaybedrivenbyoverwhelmingproinflammatorydrivers
AT nelltheo suppressionofantiinflammatorymediatorsinmetabolicdiseasemaybedrivenbyoverwhelmingproinflammatorydrivers
AT bellarysrikanth suppressionofantiinflammatorymediatorsinmetabolicdiseasemaybedrivenbyoverwhelmingproinflammatorydrivers
AT renshawderek suppressionofantiinflammatorymediatorsinmetabolicdiseasemaybedrivenbyoverwhelmingproinflammatorydrivers